Compare Eli Lilly And Co (LLY) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Sunrun Inc — how do they compare? Eli Lilly And Co trades at $1,176.52 (market cap $1.04T), while Sunrun Inc trades at $7.52 (market cap $1.83B). The key difference: Eli Lilly And Co is far larger — about 568.3× Sunrun Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Sunrun Inc for 16 Days on average.
| LLY | RUN | |
|---|---|---|
Market Cap | $1.04T | $1.83B |
Volume | 3,064,878 | 8,672,852 |
Sector | Health | Energy |
52-Week High | $1.28K | $21.41 |
52-Week Low | $799.57 | $7.59 |
Typical Hold Time | 93 Days | 16 Days |
Enterprise Value | $1.09T | $16.35B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Sunrun (RUN) trades at $7.55, down 0.79% recently, with technical indicators showing bearish momentum despite strong analyst support. The company demonstrates solid profitability with 35.29% gross margins and has beaten earnings expectations for three consecutive quarters. Recent partnerships with Tesla and Voltus highlight strategic positioning in distributed energy, though negative operating cash flow and high debt levels present challenges.
The stock appears fundamentally undervalued with a P/E of 5.16 and P/S of 0.59, while analyst consensus targets $16.33 representing 116% upside potential. However, persistent negative cash flows, high interest expenses, and solar industry headwinds from borrowing costs create significant execution risks that could limit near-term performance despite the attractive valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
